Effect of the dual sodium‐glucose co‐transporter‐1 and ‐2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
Authors' conclusion
Sotagliflozin did not adversely affect renal function or change the risk of key renal outcomes, including for participants with pre-existing renal impairment. Therefore, sotagliflozin was safe; however, further research is needed to determine its efficacy in reducing the risk of diabetic kidney disease.
Study context
- Population
- Patients with T1D and T2D, with or without renal impairment; RCTs reporting estimated glomerular filtration rate (eGFR), urinary albumin excretion or composite renal events (CRE)
- Participants
- 17,574 patients14 studies
- Comparison
- Sotagliflozin vs control
- Sotagliflozinn = 9,312
- Controln = 8,262reference
- Outcome
- Renal outcomes
Methodological detailsCochrane risk of bias 2 tool, High risk of bias was a limitation of this review
- Cochrane risk of bias 2 tool
- High risk of bias was a limitation of this review
Pooled result
As reported in the abstract
Change in eGFR, studies (n = 6) with follow-up ≥52 weeks, mL/min/1.73m2
−1.23
−1.45, −1.01
Risk of CRE (n = 6 studies), RR [95% CI]: no change, incl. in participants with renal impairment
0.82
0.61, 1.12
Further pooled results
| Outcome | RR (CI) | |
|---|---|---|
| Composite renal events (CRE) | 0.82 (0.61–1.12) | |
| 0.512Relative risk (log scale) |
- Composite renal events (CRE): n = 6 studies; no change, including in participants with renal impairment
Urinary albumin excretion
- Sotagliflozin did not significantly alter urinary albumin excretion
Baseline eGFR in studies recruiting renal impairment (4 studies)
- Baseline eGFR range
- 23.8 to 50.5 mL/min/1.73m2
Original publication
Effect of the dual sodium‐glucose co‐transporter‐1 and ‐2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials. Diabetes Obes Metab. Published 29 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →